XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 16, 2024
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Common stock, voting rights         The Company consolidates entities in which it owns more than 50% of the voting common stock and controls operations.      
Noncontrolling interest   $ 2,956,000     $ 2,956,000   $ 2,978,000  
Research and development costs   52,000 $ 82,000   230,000 $ 386,000    
Accrued interest on notes payable         793,000 795,000    
Cash equivalents   0     0   0  
Accounts receivable   15,000     $ 15,000   $ 0
Goodwill, impaired descreption         evaluated using a 26.3% discount rate and 3.0% terminal growth, indicated equity fair value far below the carrying amount, driven by limited historical revenues and sustained operating losses.      
Impairment of intangible assets         $ 0 0    
Stock based compensation expense         $ 5,000 0    
IPO [Member]                
Net of issuance costs $ 3,726,000              
Series A Convertible Preferred Shares [Member]                
Convertible preferred shares         60,496,041   60,496,041  
Stock options         880,000   880,000  
Options price, per share         $ 3.00   $ 3.00  
Expiration date         Oct. 31, 2031   Oct. 31, 2031  
Professional Fees [Member]                
Research and development costs       $ 82,000   336,000    
Selling, General and Administrative Expenses [Member]                
Stock based compensation expense         $ 5,000 $ 0    
Subsidiaries [Member]                
Noncontrolling interest   $ 2,956,000     $ 2,956,000   $ 2,978,000